Insider Selling: Abeona Therapeutics Inc (NASDAQ:ABEO) CEO Sells $119,500.00 in Stock

Abeona Therapeutics Inc (NASDAQ:ABEO) CEO Vishwas Seshadri sold 25,000 shares of Abeona Therapeutics stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $4.78, for a total value of $119,500.00. Following the completion of the transaction, the chief executive officer now owns 1,355,322 shares of the company’s stock, valued at $6,478,439.16. The trade was a 1.81 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Abeona Therapeutics Trading Up 5.2 %

Shares of Abeona Therapeutics stock opened at $4.68 on Thursday. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The company’s 50-day simple moving average is $5.38 and its 200-day simple moving average is $5.79. Abeona Therapeutics Inc has a 52-week low of $3.05 and a 52-week high of $8.45. The firm has a market cap of $227.14 million, a price-to-earnings ratio of -1.74 and a beta of 1.70.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.19. As a group, equities research analysts anticipate that Abeona Therapeutics Inc will post -1.16 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Oppenheimer began coverage on shares of Abeona Therapeutics in a report on Wednesday, March 5th. They set an “outperform” rating and a $16.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a research note on Monday, March 24th. Finally, StockNews.com upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, March 24th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $17.50.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP acquired a new stake in Abeona Therapeutics during the fourth quarter worth about $520,000. Western Standard LLC raised its holdings in Abeona Therapeutics by 22.8% in the fourth quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company’s stock valued at $11,610,000 after buying an additional 386,321 shares during the period. Squarepoint Ops LLC acquired a new position in Abeona Therapeutics during the fourth quarter valued at approximately $67,000. Twinbeech Capital LP purchased a new stake in Abeona Therapeutics during the fourth quarter worth approximately $58,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in shares of Abeona Therapeutics in the 4th quarter valued at $362,000. Institutional investors and hedge funds own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.